SGLT2 inhibitors significantly reduced the risk of COPD, pneumonia, respiratory failure, and bronchitis in both groups, with similar odds ratios and confidence intervals, suggesting consistent protective effects irrespective of T2D status. This evidence concerns the gene SLC5A2 and bronchitis.